Clal Insurance’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-13,526
Closed -$16K 147
2023
Q4
$16K Hold
13,526
﹤0.01% 117
2023
Q3
$65K Sell
13,526
-1,100
-8% -$6.16K ﹤0.01% 119
2023
Q2
$57K Hold
14,626
﹤0.01% 138
2023
Q1
$37K Hold
14,626
﹤0.01% 137
2022
Q4
$27K Buy
14,626
+1
+0% +$5 ﹤0.01% 147
2022
Q3
$99K Hold
14,625
﹤0.01% 145
2022
Q2
$158K Hold
14,625
﹤0.01% 152
2022
Q1
$328K Hold
14,625
﹤0.01% 152
2021
Q4
$413K Hold
14,625
﹤0.01% 155
2021
Q3
$954K Hold
14,625
0.01% 152
2021
Q2
$1.16M Hold
14,625
0.01% 146
2021
Q1
$1.94M Hold
14,625
0.02% 134
2020
Q4
$2.17M Hold
14,625
0.03% 99
2020
Q3
$1.54M Hold
14,625
0.03% 97
2020
Q2
$1.77M Hold
14,625
0.04% 97
2020
Q1
$1.15M Buy
14,625
+14,517
+13,442% +$2.36M 0.03% 91
2019
Q4
$585K Sell
108
-14,517
-99% -$2.93M 0.63% 43
2019
Q3
$2.64M Sell
14,625
-250
-2% -$71.1K 0.06% 81
2019
Q2
$5.93M Buy
+14,875
New +$6.26M 0.14% 65

Other funds holding ELOX

Clal Insurance's ELOX Position: Q1 2024 in Review

Clal Insurance sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q1 2024, closing a stake of 13,526 shares — an estimated $16K sold.

Clal Insurance first reported a position in ELOX in Q2 2019 and held it in 19 quarters. The position peaked at $5.93M in Q2 2019. 1 fund tracked by Wall St. Rank holds ELOX as of Q1 2024.

  • Clal Insurance reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Clal Insurance sold 13,526 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $16K.
  • Clal Insurance first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Clal Insurance's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $5.93M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Clal Insurance's 13F filing for Q1 2024, filed 9 May 2024.